Compare OMCL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMCL | SDGR |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2000 | 2020 |
| Metric | OMCL | SDGR |
|---|---|---|
| Price | $32.79 | $19.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $55.83 | $21.00 |
| AVG Volume (30 Days) | 627.2K | ★ 942.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $787,309,000.00 | $255,869,000.00 |
| Revenue This Year | $6.77 | $0.76 |
| Revenue Next Year | $5.22 | $4.60 |
| P/E Ratio | $43.69 | ★ N/A |
| Revenue Growth | 9.93 | ★ 23.29 |
| 52 Week Low | $29.06 | $10.95 |
| 52 Week High | $51.84 | $23.02 |
| Indicator | OMCL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 49.13 |
| Support Level | $32.16 | $17.23 |
| Resistance Level | $35.61 | $19.42 |
| Average True Range (ATR) | 1.20 | 0.97 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 0.95 | 2.59 |
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.